BIOPHARMA
ByIs “ChatGPT for Doctors” Driving OpenEvidence’s $12 B Valuation Surge?
January 26, 2026 | AI in Healthcare | Strategic Investment & Market Expansion OpenEvidence, the AI platform often…
Can GSK’s New Leadership Translate into Multi-Franchise Growth in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Vaccines, Immunology & Specialty Care GlaxoSmithKline (GSK) is set…
Can Gilead Sustain Growth Beyond HIV and Hepatitis in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Antivirals, Oncology & Emerging Therapies Gilead Sciences is set…
Is AstraZeneca Building the Most Diversified Growth Engine in Global Pharma?
Late January–Early February 2026 | Full-Year 2025 Earnings Preview | Oncology, CVRM & Platform Innovation AstraZeneca is expected…
Can Merck Redefine Its Growth Story Beyond Keytruda as the Patent Clock Ticks?
Late January 2026 | Full-Year 2025 Earnings Preview | Oncology, Vaccines & Post-Keytruda Strategy Merck & Co. (known…
Can Novo Nordisk Defend Its Obesity Crown as Competition With Eli Lilly Intensifies in 2026?
Late January 2026 | Full-Year 2025 Earnings Preview | Obesity & Metabolic Disease Strategy Novo Nordisk is set…
